<DOC>
	<DOCNO>NCT01086150</DOCNO>
	<brief_summary>The purpose study see investigational drug know lidocaine 5 % patch safe effective reducing symptom diabetic neuropathy , examine topical lidocaine affect nerve ending , determine whether treatment lidocaine patch prevent potential progression chronic diabetic neuropathy pain subject report pain start study .</brief_summary>
	<brief_title>Use Topical Lidocaine Reduce Pain Patients With Diabetic Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>Group 1 : 1870 year age , nondiabetic nervous system disease ( healthy control group ) Group 2 : 1870 year age Type I Type II diabetes significantly painful diabetic neuropathy ( VAS &gt; 40mm Baseline ) Group 3 : 1870 year age Type I Type II diabetes non painful insignificantly painful diabetic neuropathy ( VAS &lt; 40mm Baseline ) History clinically significant liver disease , serious peripheral vascular disease , blood clot disorder , medical condition felt exclusionary investigator Allergy lidocaine Unwillingness sign inform consent reason investigator feel subject complete study Women pregnant , breastfeed try become pregnant History slowhealing diabetic foot ulcer Current skin soft tissue lesion foot interfere application lidocaine patch skin biopsy Subjects take Class I antiarrhythmics HgA1c &gt; 11 % Active cancer within previous two year except treat basal cell carcinoma skin Comorbidities produce neuropathy Subjects take sodium channel blocker within one week study treatment throughout study Subjects take experimental drug within 30 day prior Screening Visit ( Visit 1 ) Application lidocaine patch either foot within two week Screening Visit ( Visit 1 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2010</verification_date>
</DOC>